ASP 8232

Drug Profile

ASP 8232

Alternative Names: ASP8232

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Eye disorder therapies
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Diabetic nephropathies

Most Recent Events

  • 01 Mar 2017 Astellas Pharma completes a phase II trial in Diabetic nephropathies (Adjunctive treatment) in Belgium, Czech Republic, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Spain and United Kingdom (NCT02358096)
  • 01 Aug 2016 Astellas Pharma completes a phase II trial for Diabetic macular oedema in USA (NCT02302079)
  • 01 Feb 2015 Phase-II clinical trials in Diabetic nephropathies (Adjunctive treatment) in Belgium, Czech Republic, Denmark, Hungary and United Kingdom (PO) (NCT02358096, EudraCT2014-002349-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top